These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33677052)

  • 41. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hearing preservation in patients with vestibular schwannoma treated with Gamma Knife surgery.
    Baschnagel AM; Chen PY; Bojrab D; Pieper D; Kartush J; Didyuk O; Naumann IC; Maitz A; Grills IS
    J Neurosurg; 2013 Mar; 118(3):571-8. PubMed ID: 23216466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
    Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
    J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.
    Marshall NE; Ballman KV; Michalak JC; Schomberg PJ; Burton GV; Sandler HM; Cascino TL; Jaeckle KA; Buckner JC
    J Neurooncol; 2006 May; 77(3):315-20. PubMed ID: 16273313
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation.
    Schell MJ; McHaney VA; Green AA; Kun LE; Hayes FA; Horowitz M; Meyer WH
    J Clin Oncol; 1989 Jun; 7(6):754-60. PubMed ID: 2715805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
    Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
    Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cochlea radiation dose correlates with hearing loss after stereotactic radiosurgery of vestibular schwannoma.
    Hayden Gephart MG; Hansasuta A; Balise RR; Choi C; Sakamoto GT; Venteicher AS; Soltys SG; Gibbs IC; Harsh GR; Adler JR; Chang SD
    World Neurosurg; 2013; 80(3-4):359-63. PubMed ID: 22484770
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
    Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The relevance of ototoxicity induced by radiotherapy.
    Huang Y; Zhou H; An F; Zhao A; Wu J; Wang M; Luo J
    Radiat Oncol; 2023 Jun; 18(1):95. PubMed ID: 37270526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.
    Landier W; Knight K; Wong FL; Lee J; Thomas O; Kim H; Kreissman SG; Schmidt ML; Chen L; London WB; Gurney JG; Bhatia S
    J Clin Oncol; 2014 Feb; 32(6):527-34. PubMed ID: 24419114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of hearing loss after gamma knife radiosurgery for vestibular schwannomas: age, cochlear dose, and tumor coverage.
    Brown M; Ruckenstein M; Bigelow D; Judy K; Wilson V; Alonso-Basanta M; Lee JY
    Neurosurgery; 2011 Sep; 69(3):605-13; discussion 613-4. PubMed ID: 21471832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
    Brown AL; Lupo PJ; Okcu MF; Lau CC; Rednam S; Scheurer ME
    Cancer Med; 2015 Nov; 4(11):1679-86. PubMed ID: 26400460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients.
    Gertson K; Hayashi SS; Trinkaus K; Wan F; Hayashi RJ
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):107-113. PubMed ID: 31494228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors.
    Brown AL; Foster KL; Lupo PJ; Peckham-Gregory EC; Murray JC; Okcu MF; Lau CC; Rednam SP; Chintagumpala M; Scheurer ME
    Neuro Oncol; 2017 Oct; 19(10):1372-1379. PubMed ID: 28444219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor.
    Polski B; Sosnowska-Sienkiewicz P; Szydłowski J; Januszkiewicz-Lewandowska D
    Audiol Neurootol; 2023; 28(1):32-42. PubMed ID: 36191558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
    Crabb SJ; Martin K; Abab J; Ratcliffe I; Thornton R; Lineton B; Ellis M; Moody R; Stanton L; Galanopoulou A; Maishman T; Geldart T; Bayne M; Davies J; Lamb C; Popat S; Joffe JK; Nutting C; Chester J; Hartley A; Thomas G; Ottensmeier C; Huddart R; King E
    Eur J Cancer; 2017 Dec; 87():75-83. PubMed ID: 29128692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients.
    Pan CC; Eisbruch A; Lee JS; Snorrason RM; Ten Haken RK; Kileny PR
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1393-402. PubMed ID: 15817342
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
    Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
    J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.